Treatment Pipeline

Psoriatic Disease Treatments

Drugs in the pipeline for psoriatic disease are being developed and tested, but haven’t been approved by the U.S. Food and Drug Administration (FDA). Drugs in development typically move through three phases of clinical trials on their way to obtaining approval by the FDA.

 

Clinical Trials: Phase 1

Drug development starts with preclinical studies, in which the drug is analyzed through laboratory experiments and tested in animals. Phase 1 studies involve a smaller group of participants (20 to 100 participants) to examine the safety (and dosage, if applicable) of the new treatment. Generally this phase can last several months. If the treatment or device produces positive results during Phase 1 study, it can move to Phase 2.

Clinical Trials: Phase 2

Phase 2 studies can involve up to several hundred participants to examine efficacy and side effects of a treatment over the course of several months to 2 years. If there are favorable results from the Phase 2 study, a treatment continues to Phase 3.

Clinical Trials: Phase 3

Phase 3 studies examine efficacy and monitoring of adverse reactions among 300 to 3,000 participants, studying effects in different populations and at different dosing amounts. This study can last between 1 and 4 years. At the end of the study period, the FDA will move to approve a treatment if the outcome of Phase 3 study is positive.

Clinical Trials: Phase 4 (FDA-Approved)

Phase 4 studies occur after a treatment has been approved by the FDA and generally monitors a treatment's safety and efficacy in a larger, more diverse population for a longer period of time. These studies can also focus on a certain population or question.

Clinical Trials for Psoriatic Disease

Participation in clinical trials is an essential part of finding new treatments for psoriatic disease and helps the research community move closer to finding a cure.

Learn more about clinical trials and get notified about trials near you

Learn More

Learn more about psoriatic disease treatments that are available to patients.

Connect with a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.